Petrus Trust Company LTA Sells 7,789 Shares of LivaNova PLC $LIVN

Key Points

• Petrus Trust Company LTA reduced its stake in LivaNova PLC by 55.9% in Q1, now holding 6,140 shares valued at $241,000.
• Other institutional investors like GAMMA Investing LLC and Two Sigma Advisers LP have significantly increased their holdings in LivaNova, indicating strong interest in the stock.
• Analysts have set a consensus rating of "Buy" for LivaNova, with a price target averaging $59.71, following several positive upgrades over recent months.

Petrus Trust Company LTA lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 55.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,140 shares of the company's stock after selling 7,789 shares during the quarter. Petrus Trust Company LTA's holdings in LivaNova were worth $241,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of LIVN. AQR Capital Management LLC boosted its holdings in LivaNova by 111.7% during the 1st quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock worth $60,809,000 after acquiring an additional 829,115 shares during the last quarter. Nuveen LLC purchased a new position in LivaNova during the 1st quarter worth $30,954,000. Hotchkis & Wiley Capital Management LLC boosted its holdings in LivaNova by 100.7% during the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company's stock worth $39,398,000 after acquiring an additional 503,350 shares during the last quarter. LSV Asset Management boosted its holdings in LivaNova by 278.3% during the 1st quarter. LSV Asset Management now owns 438,498 shares of the company's stock worth $17,224,000 after acquiring an additional 322,598 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in LivaNova by 13.5% during the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock worth $104,755,000 after acquiring an additional 316,993 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on LIVN. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a report on Tuesday, May 20th. Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Barclays boosted their price target on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $64.00 price target on shares of LivaNova in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $59.71.

LivaNova Stock Performance

NASDAQ LIVN traded down $0.14 during trading on Monday, hitting $56.08. 42,535 shares of the company's stock traded hands, compared to its average volume of 695,110. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of -14.42 and a beta of 0.96. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $58.91. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The business has a 50 day moving average of $49.83 and a 200-day moving average of $44.09.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.84 by $0.21. The business had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company's revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.93 earnings per share. As a group, equities research analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.